Wire · regulatory
US FDA sets up board to oversee drug exclusivity determinations
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 October 2026 · Fusion42 review
The US FDA has established a new board within the Center for Drug Evaluation and Research (CDER) to oversee drug exclusivity determinations, including decisions on the types and scope of exclusivity grants.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 16 Oct 2026 and 17 Oct 2026.
◆ ◆ The Wire takeaway
Your US market path just gained a new gatekeeper in the FDA’s exclusivity board, requiring fresh diligence on exclusivity claims. Drug developers must recheck their IP timelines or risk unexpectedly narrowed protection windows.
◆ Coverage
2 sources · first reported 16 Oct 2026 · latest 17 Oct 2026
◆ Related on Wire
◆ Topics